Advertisement
Advertisement
ORGO
Organogenesis Holdings Inc. Class A Common Stock
2.38
USDSponsored
+0.09
+4.15%
Apr 10, 15:59 UTC -4
Closed
After-Market
2.38
-0.01
-0.29%
ORGO Earnings Reports
Positive Surprise Ratio
ORGO beat 20 of 28 last estimates.
71%
Next Report
Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
$44.17M
/-$0.29
Implied change from Q4 25 (Revenue/ EPS)
-80.42%
/-193.55%
Implied change from Q1 25 (Revenue/ EPS)
-49.05%
/+190.00%
Organogenesis Holdings Inc. Class A Common Stock earnings per share and revenue
On Feb 26, 2026, ORGO reported earnings of 0.31 USD per share (EPS) for Q4 25, beating the estimate of 0.21 USD, resulting in a 44.72% surprise. Revenue reached 225.61 million, compared to an expected 176.15 million, with a 28.07% difference. The market reacted with a -13.24% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 44.17 million USD, implying an decrease of -193.55% EPS, and decrease of -80.42% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Lexeo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.27
Surprise
+15.84%
AleAnna, Inc. Class A Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-Actual
$0.00
Surprise
-
Unicycive Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.48
Actual
-$0.81
Surprise
-69.64%
Galectin Therapeutics Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.08
Surprise
+21.57%
Cardiol Therapeutics Inc. Class A Common Shares
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Centessa Pharmaceuticals plc - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.48
Surprise
-23.58%
Actinium Pharmaceuticals, Inc
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-5.04%
Scienture Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.11
Surprise
+61.48%
Jupiter Neurosciences, Inc. Common Stock
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.06
Surprise
+6.16%
Reviva Pharmaceuticals Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.19
Actual
-Surprise
-
FAQ
What were Organogenesis Holdings Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Organogenesis Holdings Inc. Class A Common Stock reported EPS of $0.31, beating estimates by 44.72%, and revenue of $225.61M, 28.07% above expectations.
How did the market react to Organogenesis Holdings Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved down -13.24%, changed from $3.70 before the earnings release to $3.21 the day after.
When is Organogenesis Holdings Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for Organogenesis Holdings Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, Organogenesis Holdings Inc. Class A Common Stock is expected to report EPS of -$0.29 and revenue of $44.17M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement